<p>在今天發佈的一份報告中，H.C. Wainwright 的 Patrick Trucchio 重申了對 Pharvaris 的買入評級，目標價為 60.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>Trucchio 關注醫療保健行業，重點關注 Atai Beckley N.V.、Definium Therapeutics 和 Alnylam Pharma 等股票。根據 TipRanks，Trucchio 推薦股票的平均回報率為 27.8%，成功率為 52.26%。</p>
<p>除了 H.C. Wainwright，Pharvaris 還在昨天的報告中獲得了 Citizens JMP 的 Jonathan Wolleben 的買入評級。然而，今天，美國銀行證券對 Pharvaris（NASDAQ: PHVS）維持了持有評級。</p>

PHVS

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

<p>H.C. Wainwright 的 Patrick Trucchio 重申了對 Pharvaris (PHVS) 的買入評級，目標價為 60.00 美元。Trucchio 負責醫療保健行業，平均回報率為 27.8%，股票推薦的成功率為 52.26%。此外，Citizens JMP 的 Jonathan Wolleben 最近也對 Pharvaris 發佈了買入評級，而美國銀行證券則維持了該股票的持有評級</p>

<p>In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Pharvaris, with a price target of $60.00.</p>
<div class="lb-trans"><p>在今天發佈的一份報告中，H.C. Wainwright 的 Patrick Trucchio 重申了對 Pharvaris 的買入評級，目標價為 60.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Trucchio covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Definium Therapeutics, and Alnylam Pharma. According to TipRanks, Trucchio has an average return of 27.8% and a 52.26% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Trucchio 關注醫療保健行業，重點關注 Atai Beckley N.V.、Definium Therapeutics 和 Alnylam Pharma 等股票。根據 TipRanks，Trucchio 推薦股票的平均回報率為 27.8%，成功率為 52.26%。</p>
</div><p>In addition to H.C. Wainwright, Pharvaris also received a Buy from Citizens JMP’s Jonathan Wolleben in a report issued yesterday. However, today, Bank of America Securities maintained a Hold rating on Pharvaris (NASDAQ: PHVS).</p>
<div class="lb-trans"><p>除了 H.C. Wainwright，Pharvaris 還在昨天的報告中獲得了 Citizens JMP 的 Jonathan Wolleben 的買入評級。然而，今天，美國銀行證券對 Pharvaris（NASDAQ: PHVS）維持了持有評級。</p>
</div>

Pharvaris (PHVS) Receives a Buy from H.C. Wainwright

Tip Ranks

Pharvaris BV

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

標普全球醫療股指數 ETF - iShares

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

醫療業 ETF - Vanguard

動態生物技術與基因組 ETF - Invesco

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - SPDR

AtaiBeckley

Definium Therapeutics

阿里拉姆制藥

Citizens Financial

美國銀行

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Pharvaris (PHVS) 獲得了 H.C. Wainwright 的買入評級